Pharmacologic class (EPC) · 12 drug pages

alpha-Adrenergic blocker: adverse event reports filed with FDA

38,454 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

38,454
reports across the class: 0.2% of all reports; 2,029
reports, 12 months to June 2026: 2,377 in the 12 months before; 76.2%
marked serious by the reporter: 57.4% across all reports; 12
drugs with a page: brand and generic names counted separately

alpha-Adrenergic blocker is a pharmacologic class (an FDA Established Pharmacologic Class) with 12 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 38,454 adverse event reports received by FDA, 0.2% of the database, from January 2004 to June 2026.

2,029 reports arrived in the 12 months to June 2026, down 15% from 2,377 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 76.2% of the class's reports are marked serious, 12.1% record death among the outcomes and 37% record hospitalisation, as reported.

Across the class the reactions recorded most often are hypotension (9.3%), dizziness (9.2%) and dyspnoea (7.9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Carvedilol	generic	14,163	700	83%	Hypotension
Tamsulosin hydrochloride	generic	5,444	539	85%	Dizziness
CoregCarvedilol	brand	4,989	29	41.4%	Dizziness
Doxazosin	generic	4,251	341	95.4%	Hypotension
Coreg CRCarvedilol phosphate	brand	2,020	3	29.3%	Dizziness
CarduraDoxazosin	brand	1,803	41	84.7%	Hypotension
Doxazosin mesylate	generic	1,731	76	92.4%	Asthma
Prazosin	generic	1,105	115	90.2%	Completed suicide
UroxatralAlfuzosin hcl	brand	844	1	39.3%	Dizziness
Silodosin	generic	755	106	88.1%	Erectile dysfunction
Terazosin	generic	703	22	73.7%	Hypotension
Alfuzosin hydrochloride	generic	646	56	85.8%	Hypotension

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Hypotensionlow blood pressure9.3%3,591
Dizzinesslight-headedness or unsteadiness9.2%3,547
Dyspnoeashortness of breath7.9%3,050
Drug ineffectivethe medicine did not work as expected7.2%2,753
Fatiguetiredness6.5%2,508
Drug interactionan interaction between medicines5.3%2,025
Syncopefainting4.5%1,745
Completed suicidedeath by suicide4.3%1,672
Astheniaweakness or lack of energy4.1%1,572
Headachehead pain3.9%1,491
Bradycardiaslow heart rate3.8%1,469
Nauseafeeling sick3.5%1,355
Falla fall3.4%1,297
Hypertensionhigh blood pressure3.4%1,296
Blood pressure increaseda raised blood pressure reading3.1%1,195
Diarrhoealoose or frequent stools3.1%1,192
Coughcough3.1%1,182
Toxicity to various agentspoisoning or toxic effect of one or more substances3%1,152
Malaisegeneral feeling of being unwell2.9%1,120
Condition aggravatedthe condition being treated got worse2.8%1,078
Off label useused for a purpose or in a way not on the label2.5%980
Asthmaasthma2.5%944
Acute kidney injurysudden loss of kidney function2.3%884
Cardiac failureheart failure2.2%861
Pain in extremitypain in an arm or leg2.2%851

Solid bar: share of all class reports. Hollow bar: the median share across the 12 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death12.1%4,670

Life-threatening7.1%2,717

Hospitalisation (initial or prolonged)37%14,219

Disability2.4%922

Congenital anomaly0.3%104

Other serious49.5%19,023

Not serious23.8%9,164

Patient age

Under 20.2%83

2 to 110.4%146

12 to 170.6%213

18 to 446.2%2,378

45 to 6420.2%7,765

65 to 7419.4%7,476

75 and over22.5%8,641

Age not given30.6%11,752

Who reported

Physician24%9,223

Pharmacist9.5%3,634

Other health professional24.1%9,275

Lawyer0.1%25

Consumer or non-health professional39.1%15,024

Not given3.3%1,273

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about alpha-Adrenergic blocker reports

Which drugs are in the alpha-Adrenergic blocker class on this site?

Carvedilol, Tamsulosin hydrochloride, Coreg, Doxazosin, Coreg CR and Cardura and 6 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

38,454 reports through June 2026, 2,029 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

hypotension (9.3%), dizziness (9.2%), dyspnoea (7.9%), drug ineffective (7.2%) and fatigue (6.5%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.